<DOC>
	<DOCNO>NCT02514551</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy alternative dose ramucirumab combination paclitaxel participant second-line metastatic locally advanced , unresectable gastric gastroesophageal junction adenocarcinoma ( GEJ ) .</brief_summary>
	<brief_title>A Study Ramucirumab ( LY3009806 ) Combination With Paclitaxel Participants With Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>The participant diagnosis gastric GEJ adenocarcinoma . The participant disease progression within 4 month last dose firstline chemotherapy within 6 month last dose neoadjuvant adjuvant therapy . The participant receive combination chemotherapy , must include platinum and/or fluoropyrimidine must include taxane antiangiogenic agent . The disease evaluable image per Response Evaluation Criteria Solid Tumors 1.1 . The participant Eastern Cooperative Oncology Group performance status 0 1 . The participant adequate organ function : Total bilirubin ≤1.5 × upper limit normal ( ULN ) alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤3 × ULN . If liver tumor involvement , AST ALT &lt; 5 × ULN . Serum creatinine ≤1.5 × ULN calculate creatinine clearance ≥50 milliliters/minute . Urinary protein &lt; 2+ . Absolute neutrophil count ≥1.5 × 10^9/liter ( L ) , platelets ≥100 × 10^9/L , hemoglobin ≥9 grams/deciliter ( 5.58 millimoles/L ) . International normalized ratio ≤1.5 × ULN partial thromboplastin time ≤5 second ULN . The participant estimate life expectancy minimum 12 week . The participant resolution Grade 1 less Common Terminology Criteria Adverse Events Version 4.0 , clinically significant toxic effect previous therapy . The participant , male , sterile agrees use reliable method birth control . The participant , female , surgically sterile , postmenopausal , agree use highly effective method birth control . The participant , female childbearing potential , must negative pregnancy test . The participant receiving therapy follow : Nonsteroidal antiinflammatory agent . Other antiplatelet agent ; Aspirin use dose 325 milligram ( mg ) /day permit . The participant receive radiotherapy within 14 day prior randomization . The participant receive previous chemotherapy cumulative dose &gt; 900 mg per meter square ( mg/m^2 ) epirubicin &gt; 400 mg/m^2 doxorubicin . The participant document brain metastasis leptomeningeal disease . The participant significant bleed disorder vasculitis . The participant experience arterial thromboembolic event within 6 month . The participant symptomatic congestive heart failure symptomatic cardiac arrhythmia . The participant uncontrolled hypertension , despite antihypertensive intervention . The participant underwent major surgery within 28 day . The participant history gastrointestinal perforation fistula within 6 month . The participant history inflammatory bowel disease Crohn 's disease require medical intervention within 12 month . The participant bowel obstruction history chronic diarrhea consider clinically significant . The participant either following : Childpugh B C cirrhosis . The participant serious illness medical condition include : Human immunodeficiency virus infection . The participant concurrent active malignancy follow : Nonmelanomatous skin cancer . In situ carcinoma cervix noninvasive carcinoma situ neoplasm . The participant serious nonhealing : ( ) wound , ( b ) peptic ulcer , ( c ) bone fracture . The participant experience Grade 3 4 venous thromboembolic event adequately treat .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>stomach cancer</keyword>
</DOC>